Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women

Sarah Palmer, Valerie F. Boltz, Jeremy Y. Chow, Neil A. Martinson, James A. McIntyre, Glenda E. Gray, Mark J. Hopley, Douglas Mayers, Patrick Robinson, David B. Hall, Frank Maldarelli, John M. Coffin, John W. Mellors

Research output: Contribution to journalArticle

Abstract

Background: In the Treatment Options Preservation Study (TOPS) trial, 4 or 7 days of Combivir (CBV; zidovudine/lamivudine) with maternal single-dose nevirapine (sdNVP) significantly reduced the emergence of NVP resistance as determined by virus population genotyping. To detect NVP resistance with greater sensitivity, we analysed TOPS samples by allele-specific real-time PCR (ASP). Methods: In a random subset of women from each arm of the trial, plasma samples from before and 6 weeks after sdNVP were analysed using ASP at codons 103, 181, 184 and 190. Results: Samples were analysed from 27 women in the sdNVP arm and 24 each in the CBV 4-day (sdNVP/CBV4) and 7-day (sdNVP/CBV7) arms. ASP detected NVP-resistant variants in week 6 samples from 70% of women in the sdNVP arm, 29% in the sdNVP/CBV4 arm and 33% in sdNVP/CBV7 arm (P

Original languageEnglish (US)
Pages (from-to)327-336
Number of pages10
JournalAntiviral Therapy
Volume17
Issue number2
DOIs
StatePublished - 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women'. Together they form a unique fingerprint.

  • Cite this

    Palmer, S., Boltz, V. F., Chow, J. Y., Martinson, N. A., McIntyre, J. A., Gray, G. E., Hopley, M. J., Mayers, D., Robinson, P., Hall, D. B., Maldarelli, F., Coffin, J. M., & Mellors, J. W. (2012). Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Antiviral Therapy, 17(2), 327-336. https://doi.org/10.3851/IMP1946